An observational study in Diabetes Mellitus and Diabetes Mellitus, Type 1, sponsored by Second Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Second Xiangya Hospital of Central South University · Observational
Among 21 studies in Diabetes Mellitus, Type 1 by Second Xiangya Hospital of Central South University — 13 open to participants now, 13 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Second Xiangya Hospital of Central South University.
Among the 21 studies in Diabetes Mellitus, Type 1 by Second Xiangya Hospital of Central South University, this one is one of 3 that started in 2025, is one of 9 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 20th registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 2,950 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →13 of the 21 studies in Diabetes Mellitus, Type 1 by Second Xiangya Hospital of Central South University are open now, in 1 country. Each count lists the studies.
Of the 411 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 257 (63%) stop at 75 or younger; 184 take children under 18; 64 take healthy volunteers.
This study: 14 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 4 4
First in 2010; this study’s year is marked. 3 started in 2025.
Median enrollment 50 across the 12 interventional studies, 2,110 across the 9 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
Second Xiangya Hospital of Central South University is the lead sponsor of 87 studies on the registry; 50 are open to participants now.
4 of the studies in Diabetes Mellitus, Type 1 by Second Xiangya Hospital of Central South University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06496412Second Xiangya Hospital of Central South UniversitySafety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM | 2026-12-30 |
| NCT07097818Second Xiangya Hospital of Central South UniversityEfficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2 | 2027-03-01 |
| NCT07835724Second Xiangya Hospital of Central South UniversityEnvironmental Determinants of Type 1 Diabetes Risk | 2027-07-01 |
| NCT04096794Second Xiangya Hospital of Central South UniversityChinese Alliance for Type 1 Diabetes Multi-center Collaborative Research | 2027-09 |
Among the 21 studies in Diabetes Mellitus, Type 1 by Second Xiangya Hospital of Central South University, from their registry updates:
Nothing recorded among them since 2026-09-25.
The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is:
This study is a nested case-control study, in which a case group and a control group are set up for the collection of observational indicators. Case group: Diabetic patients who "progressed to insulin deficiency" and those who "progressed to severe insulin deficiency". Control group: Patients who did not progress to insulin deficiency. The study period is 3 years.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 2,950 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Second Xiangya Hospital of Central South University is the lead sponsor of 87 studies on the registry; 50 are open to participants now.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
This study will enroll newly-diagnosed diabetic patients whose clinical subtype is unclear. Participants must be aged between 14 and 50 years, with a diabetes diagnosis within the past year, confirmed by standard American Diabetes Association (ADA) criteria. A key pathophysiological criterion is a peak C-peptide level \< 200 pmol/L, suggesting impaired insulin secretion.
Key Exclusion Criteria: Patients will be excluded for conditions that could confound the etiology of diabetes or pose additional risks, including:
Specific diabetes subtypes (e.g., gestational diabetes, monogenic diabetes, pancreatic diseases).
Comorbidities such as malignant tumors or severe organ dysfunction. Acute metabolic derangements (e.g., ketoacidosis). Conditions limiting life expectancy or ability to participate (e.g., expected survival \< 3 years, psychiatric disorders).
Current pregnancy or lactation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of diabetes within \< 1 year:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with diabetes who 'progress to insulin deficiency' and 'progress to severe insulin deficiency'
For each case, several controls (1:2) were randomly selected from patients in this cohort who had not progressed to insulin deficiency at the same follow - up time point.
C-peptide
The primary endpoint is the occurrence of progression to insulin deficiency. Subjects who "progress to insulin deficiency" are defined as those whose C-peptide level drops to C-peptide \< 250 pmol/L during the follow - up period;
Time frame: "baseline"、"third year"
Fasting and 2 - hour blood glucose
Time frame: "baseline"、"third year"
Glycosylated hemoglobin
Time frame: "baseline"、"third year"
Whether insulin treatment is needed
Collect the medical history and current medication information of the subjects.
Time frame: "baseline"、"third year"
Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.
Of 249 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 50 months is above that.
Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Xiangya Hospital of Central South University